Method of treating cancer with anti-neurotrophin agents
AssigneeCephalon, Inc.
InventorsKaren J. Buchkovich, Craig A. Dionne, Sheila J. Miknyoczki, Bruce A. Ruggeri
Life of this patent
Estimating the term…
Abstract
A method of treating or preventing cancer by administering to a mammal a therapeutically effective amount of at least one anti-neurotrophin agent is described. The anti-neurotrophin agent is preferably an anti-neurotrophin antibody, an antisense molecule directed to a neurotrophin, a small organic molecule which binds a neurotrophin, or a dominant-negative mutation of a trk receptor that binds a neurotrophin. This method is particularly preferred for the treatment of prostate or pancreatic cancer. The anti-neurotrophic agents neutralize NGF, BDNF, NT-3, NT-4/5, NT-6 or NT-7 and include humanized antibodies as well as fragments thereof.
Claims15
A method of treating cancer comprising administering to a mammal a therapeutically effective amount of at least one anti-neurotrophin antibody, wherein said cancer is a neoplasm that expresses neurotrophin receptors.
A method of treating cancer comprising administering to a mammal a therapeutically effective amount of at least one anti-neurotrophin antibody, wherein said cancer is prostate or pancreatic cancer.
A method of treating prostate or pancreatic tumors comprising contacting said tumor with a therapeutically effective amount of at least one neutralizing neurotrophin antibody, wherein said neurotrophin is selected from the group consisting of NGF, BDNF, NT-3, NT-4/5, NT-6, and NT-7.
A method of reducing prostatic or pancreatic tumor volume comprising contacting said tumor with at least one anti-neurotrophin antibody.
A method of reducing prostatic or pancreatic tumor growth rate comprising contacting said tumor with at least one anti-neurotrophin antibody.
Dependencies are inferred from the claim text.